In December last year, Evaxion secured the FDA approval to advance with its Phase IIb clinical trial, where EVX-01 is given along with KEYTRUDA to patients with metastatic
The post US FDA grants fast track designation to Evaxion Biotech’s personalised cancer therapy appeared first on Pharmaceutical Business review.